Roles of Glycogen Synthase Kinase-3 in Alzheimer's Disease: From Pathology to Treatment Target

Hsing Cheng Liu, Sy Jye Leu, De Maw Chuang

研究成果: 雜誌貢獻文章

6 引文 (Scopus)

摘要

Alzheimer's disease (AD) is a progressive neurodegenerative disorder with an unknown cause, and as of yet there is no effective treatment. The neuropathological hallmarks of AD include amyloid plaques and neurofibrillary tangle (NFT) deposits. There is evidentiary support for amyloid deposition being the primary influence driving AD pathogenesis, commonly referred to as the amyloid hypothesis of AD. But brain amyloid load is not correlated with AD severity; instead, NFT formation has been shown to be associated with disease progression. Therefore, advocates of the tau hypothesis strongly postulate that NFT accumulation is critical for neuronal loss and AD development. Hence, inhibition of NFT formation/accumulation is one of the treatment strategies to combat AD. NFTs consist of aggregations of paired helical hyperphosphorylated tau protein, one of the major microtubule-associated proteins. The hyperphosphorylation of tau impairs its normal maintenance function for cytoskeleton stability, and induces a toxic sequestration of normal tau and other microtubule-associated proteins. Glycogen synthase kinase-3 (GSK-3) is the main enzyme that phosphorylates tau, and an increase in GSK-3 activity has been observed in AD patients. GSK-3 inhibition by lithium, a major mood stabilizer that is used to treat bipolar disorder, has been shown to reduce tau phosphorylation and even decrease amyloid burden in the brain of AD animal models. This supports the notion of GSK-3 inhibition as a potential avenue for AD treatment.

原文英語
頁(從 - 到)135-139
頁數5
期刊Journal of Experimental and Clinical Medicine(Taiwan)
4
發行號3
DOIs
出版狀態已發佈 - 六月 2012

指紋

Glycogen Synthase Kinase 3
Alzheimer Disease
Pathology
Neurofibrillary Tangles
Amyloid
Therapeutics
Microtubule-Associated Proteins
tau Proteins
Poisons
Amyloid Plaques
Brain Diseases
Cytoskeleton
Bipolar Disorder
Lithium
Neurodegenerative Diseases
Disease Progression
Animal Models
Maintenance
Phosphorylation

ASJC Scopus subject areas

  • Medicine(all)

引用此文

Roles of Glycogen Synthase Kinase-3 in Alzheimer's Disease : From Pathology to Treatment Target. / Liu, Hsing Cheng; Leu, Sy Jye; Chuang, De Maw.

於: Journal of Experimental and Clinical Medicine(Taiwan), 卷 4, 編號 3, 06.2012, p. 135-139.

研究成果: 雜誌貢獻文章

@article{c3f588497fb048ff82802bbccd1a1946,
title = "Roles of Glycogen Synthase Kinase-3 in Alzheimer's Disease: From Pathology to Treatment Target",
abstract = "Alzheimer's disease (AD) is a progressive neurodegenerative disorder with an unknown cause, and as of yet there is no effective treatment. The neuropathological hallmarks of AD include amyloid plaques and neurofibrillary tangle (NFT) deposits. There is evidentiary support for amyloid deposition being the primary influence driving AD pathogenesis, commonly referred to as the amyloid hypothesis of AD. But brain amyloid load is not correlated with AD severity; instead, NFT formation has been shown to be associated with disease progression. Therefore, advocates of the tau hypothesis strongly postulate that NFT accumulation is critical for neuronal loss and AD development. Hence, inhibition of NFT formation/accumulation is one of the treatment strategies to combat AD. NFTs consist of aggregations of paired helical hyperphosphorylated tau protein, one of the major microtubule-associated proteins. The hyperphosphorylation of tau impairs its normal maintenance function for cytoskeleton stability, and induces a toxic sequestration of normal tau and other microtubule-associated proteins. Glycogen synthase kinase-3 (GSK-3) is the main enzyme that phosphorylates tau, and an increase in GSK-3 activity has been observed in AD patients. GSK-3 inhibition by lithium, a major mood stabilizer that is used to treat bipolar disorder, has been shown to reduce tau phosphorylation and even decrease amyloid burden in the brain of AD animal models. This supports the notion of GSK-3 inhibition as a potential avenue for AD treatment.",
keywords = "Alzheimer's disease, Beta-amyloid, Glycogen synthase kinase-3, Lithium, Neurofibrillary tangle, Tau",
author = "Liu, {Hsing Cheng} and Leu, {Sy Jye} and Chuang, {De Maw}",
year = "2012",
month = "6",
doi = "10.1016/j.jecm.2012.04.001",
language = "English",
volume = "4",
pages = "135--139",
journal = "Journal of Experimental and Clinical Medicine",
issn = "1878-3317",
publisher = "Elsevier Taiwan LLC",
number = "3",

}

TY - JOUR

T1 - Roles of Glycogen Synthase Kinase-3 in Alzheimer's Disease

T2 - From Pathology to Treatment Target

AU - Liu, Hsing Cheng

AU - Leu, Sy Jye

AU - Chuang, De Maw

PY - 2012/6

Y1 - 2012/6

N2 - Alzheimer's disease (AD) is a progressive neurodegenerative disorder with an unknown cause, and as of yet there is no effective treatment. The neuropathological hallmarks of AD include amyloid plaques and neurofibrillary tangle (NFT) deposits. There is evidentiary support for amyloid deposition being the primary influence driving AD pathogenesis, commonly referred to as the amyloid hypothesis of AD. But brain amyloid load is not correlated with AD severity; instead, NFT formation has been shown to be associated with disease progression. Therefore, advocates of the tau hypothesis strongly postulate that NFT accumulation is critical for neuronal loss and AD development. Hence, inhibition of NFT formation/accumulation is one of the treatment strategies to combat AD. NFTs consist of aggregations of paired helical hyperphosphorylated tau protein, one of the major microtubule-associated proteins. The hyperphosphorylation of tau impairs its normal maintenance function for cytoskeleton stability, and induces a toxic sequestration of normal tau and other microtubule-associated proteins. Glycogen synthase kinase-3 (GSK-3) is the main enzyme that phosphorylates tau, and an increase in GSK-3 activity has been observed in AD patients. GSK-3 inhibition by lithium, a major mood stabilizer that is used to treat bipolar disorder, has been shown to reduce tau phosphorylation and even decrease amyloid burden in the brain of AD animal models. This supports the notion of GSK-3 inhibition as a potential avenue for AD treatment.

AB - Alzheimer's disease (AD) is a progressive neurodegenerative disorder with an unknown cause, and as of yet there is no effective treatment. The neuropathological hallmarks of AD include amyloid plaques and neurofibrillary tangle (NFT) deposits. There is evidentiary support for amyloid deposition being the primary influence driving AD pathogenesis, commonly referred to as the amyloid hypothesis of AD. But brain amyloid load is not correlated with AD severity; instead, NFT formation has been shown to be associated with disease progression. Therefore, advocates of the tau hypothesis strongly postulate that NFT accumulation is critical for neuronal loss and AD development. Hence, inhibition of NFT formation/accumulation is one of the treatment strategies to combat AD. NFTs consist of aggregations of paired helical hyperphosphorylated tau protein, one of the major microtubule-associated proteins. The hyperphosphorylation of tau impairs its normal maintenance function for cytoskeleton stability, and induces a toxic sequestration of normal tau and other microtubule-associated proteins. Glycogen synthase kinase-3 (GSK-3) is the main enzyme that phosphorylates tau, and an increase in GSK-3 activity has been observed in AD patients. GSK-3 inhibition by lithium, a major mood stabilizer that is used to treat bipolar disorder, has been shown to reduce tau phosphorylation and even decrease amyloid burden in the brain of AD animal models. This supports the notion of GSK-3 inhibition as a potential avenue for AD treatment.

KW - Alzheimer's disease

KW - Beta-amyloid

KW - Glycogen synthase kinase-3

KW - Lithium

KW - Neurofibrillary tangle

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=84862023165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862023165&partnerID=8YFLogxK

U2 - 10.1016/j.jecm.2012.04.001

DO - 10.1016/j.jecm.2012.04.001

M3 - Article

AN - SCOPUS:84862023165

VL - 4

SP - 135

EP - 139

JO - Journal of Experimental and Clinical Medicine

JF - Journal of Experimental and Clinical Medicine

SN - 1878-3317

IS - 3

ER -